Table 1

Characteristics of study patients

Overall population (n=279)LPR group (n=84)Non-LPR group (n=195)p Value
Age (years), mean±SD64.7±12.561.8±14.166.0±11.50.01
Female, n (%)136 (48.7%)41 (48.8%)95 (48.7%)0.80
Body mass index (kg/m2), mean±SD23.1±3.322.9±3.7123.1±3.220.55
Diabetes mellitus, n (%)72 (25.8%)16 (19.0%)56 (28.7%)0.09
Hypertension, n (%)156 (55.9%)41 (48.8%)115 (58.9%)0.11
Hyperlipidemia, n (%)160 (57.3%)45 (53.5%)115 (58.9%)0.40
Ischemic heart disease, n (%)47 (16.8%)10 (11.9%)37 (18.9%)0.14
Hemoglobin (g/dL), mean±SD12.9±1.6613.4±1.5412.6±1.66<0.01
Hematocrit, mean±SD39.1±4.5940.9±4.2938.4±4.52<0.01
Creatinine (mg/dL), mean±SD1.00±1.180.97±1.261.01±1.140.82
eGFR (mL/min/1.73 m2), mean±SD68.8±22.671.0±24.267.9±21.90.29
Platelet count (×104/mL), mean±SD20.7±5.2822.4±5.6320.0±4.97<0.01
Maximum sheath size, n (%)0.29
 5Fr3 (1.0%)2 (1.0%)1 (0.5%)
 6Fr68 (24.3%)19 (22.6%)49 (25.1%)
 7Fr108 (38.7%)35 (41.6%)73 (37.4%)
 8Fr87 (31.1%)22 (26.1%)65 (33.3%)
 9Fr13 (4.6%)6 (7.1%)7 (3.5%)
Multiple access sites, n (%)38 (13.6%)17 (20.2%)21 (10.7%)0.03
Percutaneous closure device, n (%)241 (86.3%)73 (86.9%)168 (86.1%)0.28
Maximum ACT (s), mean±SD341±71.6349±74.5337±70.20.22
Clopidogrel regimen, n (%)
 Loading dose, 600 mg56 (20.5%)15 (18.1%)41 (21.6%)0.73
 Maintenance dose, 75 mg >5 days217 (79.4%)68 (81.9%)149 (78.4%)
Statin therapy, n (%)158 (56.6%)32 (38.1%)89 (45.6%)0.24
PPI, n (%)174 (62.3%)53 (63.1%)121 (62.0%)0.86
PRU, mean±SD227±92.2119±44.0273±64.3<0.01
  • ACT, activated clotting time; eGFR, estimated glomerular filtration rate; LPR, low platelet reactivity; PPI, proton pump inhibitor; PRU, P2Y12 reaction unit.